Vifor Pharma Group is a global specialty pharmaceuticals company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions.
The company strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company began by building a world-class portfolio in iron deficiency and then used this platform to expand into other areas.
Vifor Pharma Group aims to be a global leader in iron deficiency, nephrology and cardio-renal therapies.
Our main therapeutic areas are:
- Rare diseases
- Specialty cardiology
We have a strong portfolio of class-leading products, such as Venofer® for dialysis; Ferinject® for heart failure, gastroenterology and women’s health; and Maltofer® for more general applications.
In nephrology, Vifor Pharma has created a joint company with Fresenius Medical Care, the world leader in dialysis services, thereby gaining direct access to chronic kidney disease patients and nephrologists alike. The relationship has proven effective, as demonstrated by the successful introduction of Mircera® in the US dialysis market and the dominant position retained with Venofer® for the treatment of iron-deficiency anaemia in patients on dialysis. In the renal space, the pipeline product Rayaldee®, a treatment for patients with secondary hyperparathyroidism (SHPT) is currently in phase III clinical development.
With the acquisition of Relypsa, a US based biopharmaceutical company leading the discovery, development and commercialisation of polymer-based medicines to treat conditions that are often overlooked and undertreated, Vifor Pharma becomes a significant player in cardio-renal care in the USA. Relypsa developed Veltassa®, a potassium binder approved in the USA for the treatment of hyperkalaemia, a condition that can have a serious impact on patient lives or even be life-threatening. Veltassa® is expected to launch across Europe later in 2017.
In rare and ultra-rare diseases, Vifor Pharma entered into a strategic alliance with US-based company ChemoCentryx (CCXI) in 2016. Vifor Pharma thereby gained development and commercialization rights to CCX168 and CCX140 for the treatment of various rare diseases such as Focal Segmental Glomerulosclerosis (FSGS), ANCA-associated vasculitis or C3 Glomerulopathy among others.
For Global Business Development inquiries, please contact: